CL2009001080A1 - Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo. - Google Patents

Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.

Info

Publication number
CL2009001080A1
CL2009001080A1 CL2009001080A CL2009001080A CL2009001080A1 CL 2009001080 A1 CL2009001080 A1 CL 2009001080A1 CL 2009001080 A CL2009001080 A CL 2009001080A CL 2009001080 A CL2009001080 A CL 2009001080A CL 2009001080 A1 CL2009001080 A1 CL 2009001080A1
Authority
CL
Chile
Prior art keywords
vehicle
carrier
solubilizing
emulsifying
dissolving
Prior art date
Application number
CL2009001080A
Other languages
English (en)
Spanish (es)
Inventor
Irene Papanicolaou
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2009001080A1 publication Critical patent/CL2009001080A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2009001080A 2008-05-06 2009-05-05 Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo. CL2009001080A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
CL2009001080A1 true CL2009001080A1 (es) 2010-09-24

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2009001080A CL2009001080A1 (es) 2008-05-06 2009-05-05 Procedimiento para encapsular agentes biologicamente activos en un vehiculo en forma de particulas, que comprende solubilizar en un agente de apareamiento de ion hidrofobo y un disolvente, disolver, formar la emulsion y obtener el vehiculo; vehiculo en forma de particulas; y composicion farmaceutica que comprende el vehiculo.
CL2009001076A CL2009001076A1 (es) 2008-05-06 2009-05-05 Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
CL2009001077A CL2009001077A1 (es) 2008-05-06 2009-05-05 Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
CL2009001081A CL2009001081A1 (es) 2008-05-06 2009-05-05 Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo.

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2009001076A CL2009001076A1 (es) 2008-05-06 2009-05-05 Nanoparticulas que comprende una sustancia formadora de particulas y una proteina; composicion que comprende dichas nanoparticulas; procedimiento para suministrar una proteina a traves de la membrana hematoencefalica; uso de la composicion para profilaxis o tratar enfermedades del sistema nervioso central.
CL2009001077A CL2009001077A1 (es) 2008-05-06 2009-05-05 Vehiculo particulado polimerico que comprende un agente biologico en fase acuosa en un lumen hueco; procedimiento para suministrar una proteina en el ojo; composicion farmaceutica que comprende dicho vehiculo; y su uso para profilaxis y tratar enfermedades o trastornos del ojo.
CL2009001081A CL2009001081A1 (es) 2008-05-06 2009-05-05 Procedimiento para producir un vehiculo en forma de particulas que comprende disolver polibutilcianoacrilado en un disolvente organico para formar una solucion polimerica, anadir una solucion acuosa, mezclar y obtener el vehiculo en forma de particulas; composicion farmaceutica que comprende dicho vehiculo.

Country Status (11)

Country Link
US (1) US20110064821A1 (enExample)
EP (2) EP2271323A2 (enExample)
JP (1) JP2011522792A (enExample)
KR (3) KR20110015604A (enExample)
AR (4) AR072359A1 (enExample)
CA (1) CA2721241A1 (enExample)
CL (4) CL2009001080A1 (enExample)
PE (4) PE20091964A1 (enExample)
TW (4) TW201012488A (enExample)
UY (4) UY31808A (enExample)
WO (1) WO2009135853A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010012137A (es) * 2008-05-06 2010-12-17 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos.
WO2013021353A1 (en) 2011-08-11 2013-02-14 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
EP3148590A1 (en) * 2014-05-30 2017-04-05 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
WO2015181344A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
EP3154524B1 (en) * 2014-06-12 2021-12-15 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
WO2015200054A2 (en) 2014-06-24 2015-12-30 The Trustees Of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
JP2021501753A (ja) * 2017-11-03 2021-01-21 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 徐放性ナノキャリア製剤を形成するための疎水性イオン対化およびフラッシュナノ沈殿
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
WO2020056323A1 (en) * 2018-09-13 2020-03-19 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
MX2021015457A (es) 2019-06-14 2022-04-06 Univ Princeton Formulaciones de dihidromiricetina y un permeabilizante.
KR20260035768A (ko) * 2024-09-06 2026-03-13 오즈온바이오 주식회사 펩타이드 약물의 경구 투여를 위한 펩타이드 약물 및 카운터 이온을 포함한 소수성 이온쌍 복합체 조성물 및 이의 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
WO1994017789A1 (en) * 1993-02-15 1994-08-18 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
HUT74509A (en) * 1993-09-09 1997-01-28 Schering Ag Active principles and gas containing microparticles, their use for realising active principles in ultrasonically controlled manner, and process for preparing them
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP2005514326A (ja) * 2001-07-10 2005-05-19 コリクサ コーポレイション ミクロスフェア中に封入されたタンパク質およびアジュバントを送達するための組成物および方法
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
CA2531238C (en) 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
JP2008513363A (ja) 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
KR101263294B1 (ko) 2006-03-30 2013-06-04 글락소 그룹 리미티드 아밀로이드­베타 펩티드에 대한 항체
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
CA2683801A1 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists

Also Published As

Publication number Publication date
CL2009001077A1 (es) 2010-09-24
UY31809A (es) 2009-12-14
WO2009135853A3 (en) 2011-05-12
TW201012488A (en) 2010-04-01
CL2009001076A1 (es) 2010-09-24
TW201012490A (en) 2010-04-01
PE20091829A1 (es) 2009-12-12
PE20091882A1 (es) 2009-12-24
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
CA2721241A1 (en) 2009-11-12
AR071634A1 (es) 2010-06-30
KR20110010760A (ko) 2011-02-07
EP2271323A2 (en) 2011-01-12
CL2009001081A1 (es) 2010-09-24
US20110064821A1 (en) 2011-03-17
UY31807A (es) 2009-12-14
EP2441447A1 (en) 2012-04-18
AR071633A1 (es) 2010-06-30
JP2011522792A (ja) 2011-08-04
KR20110010758A (ko) 2011-02-07
KR20110015604A (ko) 2011-02-16
AR072668A1 (es) 2010-09-15
TW201012489A (en) 2010-04-01
UY31808A (es) 2009-12-14
WO2009135853A2 (en) 2009-11-12
UY31810A (es) 2009-12-14
AR072359A1 (es) 2010-08-25
PE20091965A1 (es) 2010-01-09

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
AR060165A1 (es) Proteina de suero como vehiculo de entrega para un agente activo
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
BRPI0810899A2 (pt) Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais.
CY1122617T1 (el) Απαλλαγμενες prion συνθεσεις νανοσωματιδιων και μεθοδοι
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
AR053466A1 (es) Un sistema de suministro para componentes activos como parte de una composicion comestible que incluye una relacion de material encapsulante y componente activo
PE20091964A1 (es) Encapsulacion de agentes biologicamente activos
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
BRPI0416613A (pt) composição e forma de dosagem compreendendo uma molécula anfifìlica como um veìculo de suspensão
MX2015014312A (es) Metodo para tratar un sustrato hecho de fibras animales con particulas solidas y una formulacion quimica que comprende un colorante.
BR112012006635A2 (pt) partículas de fosfato de cálcio uniformes, rígidas, esféricas, nanoporosas carregadas de agente ativo e métodos de fazer e usar as mesmas
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
AR053467A1 (es) Un sistema de suministro para componentes activos como parte de una composicion comestible que tiene tamano de particulas seleccionado
GT200500045A (es) Solidos supersaturados estabilizados de drogas lipofilicas
BR112013018352A2 (pt) composição de minociclina tópica e método
FI20116138A7 (fi) Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen
MX2009005696A (es) Nanoparticulas magneticas para la aplicacion en hipertermia, preparacion de las mismas y uso en constructos que tienen una aplicacion farmacologica.
MY161272A (en) Compositions comprising metallated malodor control polymers
EA201301264A1 (ru) Способ получения неорганического материала в виде частиц
EA201891159A1 (ru) Наносистемы для контролируемого транспорта активных молекул диагностического, прогностического и терапевтического назначения
TR201904884T4 (tr) Koloni̇k boşaltmada kullanima yöneli̇k formülasyonlar ve formülasyonlarin üreti̇m yöntemleri̇
FR2969653B1 (fr) Dispersion organique de particules a base de fer sous forme cristallisee